We have a path to clinical trials for those with Usher Syndrome.
After $3.5 million, almost a decade, and a dozen research programs supported, Usher 2020 is ready to move treatments to clinical trials for those with Usher Syndrome and Retinitis Pigmentosa.
What Have We Done?
Usher 2020 has spent years funding cutting-edge research in small molecule therapy, gene therapy, and stem cell therapy. We are proud to have partnered with some of the most respected and experienced clinicians and researchers in the field of rare inherited retinal diseases like Usher Syndrome.
What Will We Do Now?
Our work has brought us to a point where we are prepared to move some of these therapies into clinical trials. But we know what a daunting task that is.
Several years ago, as we attempted to move our first prospective treatment to trial, we determined that the current model to do so was not going to work for a rare disease. So, Usher 2020 collaborated with Massachusetts Eye and Ear (MEEI) to create Odylia Therapeutics, non-profit biotech dedicated to moving rare retinal disease therapies to clinical trials for patients. With the help of Odylia, we have a clear path to bring a gene therapy treatment for Usher Syndrome to a clinical trial.
In addition, we are supporting the first ever drug therapy to help slow the degeneration of sight for those with Retinitis Pigmentosa. Our hope is to have this treatment available to all those with RP by the year 2025.